$546 Million is the total value of Versant Venture Management, LLC's 11 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | CRISPR Therapeutics AG | $303,752,000 | -99.9% | 3,631,656 | -13.2% | 55.60% | +25.9% |
| ADVM | Adverum Biotechnologies, Inc. | $72,140,000 | -100.0% | 7,003,892 | 0.0% | 13.20% | -37.2% | |
| APRE | Aprea Therapeutics, Inc. | $44,613,000 | -99.9% | 1,854,229 | 0.0% | 8.16% | -21.0% | |
| FLXN | New | Flexion Therapeutics, Inc. | $40,001,000 | – | 3,842,578 | +100.0% | 7.32% | – |
| CRNX | Crinetics Pharmaceuticals, Inc. | $31,820,000 | -99.9% | 2,030,616 | 0.0% | 5.82% | +14.0% | |
| AKRO | Sell | Akero Therapeutics, Inc. | $23,946,000 | -100.0% | 777,727 | -63.2% | 4.38% | -42.1% |
| OCUL | Ocular Therapeutix, Inc. | $16,859,000 | -99.9% | 2,215,384 | 0.0% | 3.09% | +16.4% | |
| GRTS | Gritstone Oncology, Inc. | $8,223,000 | -100.0% | 3,102,929 | 0.0% | 1.50% | -49.2% | |
| CBAY | CymaBay Therapeutics, Inc. | $3,937,000 | -99.8% | 543,753 | 0.0% | 0.72% | +164.1% | |
| CLVS | Clovis Oncology, Inc. | $594,000 | -99.9% | 101,855 | 0.0% | 0.11% | +10.1% | |
| EYES | Second Sight Medical Products, Inc. | $484,000 | -99.9% | 561,612 | 0.0% | 0.09% | +12.7% | |
| ISEE | Exit | IVERIC bio, Inc. | $0 | – | -1,724,909 | -100.0% | -1.26% | – |
| VCYT | Exit | Veracyte, Inc. | $0 | – | -1,205,407 | -100.0% | -4.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.